COVID-19 对有和无预先存在的消化系统疾病的个体的影响，特别关注老年患者。
Impact of COVID-19 in individuals with and without pre-existent digestive disorders with a particular focus on elderly patients.
机构信息
CEMAD, Center for Diagnosis and Treatment of Digestive Diseases, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Roma 00168, Italy.
CEMAD, Università Cattolica del Sacro Cuore, Roma 00168, Italy.
出版信息
World J Gastroenterol. 2023 Jul 14;29(26):4099-4119. doi: 10.3748/wjg.v29.i26.4099.
Abstract
Coronavirus disease 2019 (COVID-19) has several extrapulmonary symptoms. Gastrointestinal (GI) symptoms are among the most frequent clinical manifestations of COVID-19, with severe consequences reported in elderly patients. Furthermore, the impact of COVID-19 on patients with pre-existing digestive diseases still needs to be fully elucidated, particularly in the older population. This review aimed to investigate the impact of COVID-19 on the GI tract, liver, and pancreas in individuals with and without previous digestive diseases, with a particular focus on the elderly, highlighting the distinctive characteristics observed in this population. Finally, the effectiveness and adverse events of the anti-COVID-19 vaccination in patients with digestive disorders and the peculiarities found in the elderly are discussed.
摘要
新型冠状病毒病 2019（COVID-19）有多种肺外症状。胃肠道（GI）症状是 COVID-19 最常见的临床表现之一，在老年患者中报告了严重的后果。此外，COVID-19 对患有既往消化疾病的患者的影响仍需要充分阐明，特别是在老年人群中。本综述旨在研究 COVID-19 对有和没有既往消化疾病的个体的胃肠道、肝脏和胰腺的影响，特别关注老年人，强调在该人群中观察到的特征。最后，讨论了 COVID-19 疫苗在消化系统疾病患者中的有效性和不良反应，以及老年人中发现的特殊性。
相似文献
1
Impact of COVID-19 in individuals with and without pre-existent digestive disorders with a particular focus on elderly patients.COVID-19 对有和无预先存在的消化系统疾病的个体的影响，特别关注老年患者。
World J Gastroenterol. 2023 Jul 14;29(26):4099-4119. doi: 10.3748/wjg.v29.i26.4099.
2
Implications of SARS-COV-2 infection in the diagnosis and management of the pediatric gastrointestinal disease.SARS-CoV-2 感染对儿科胃肠疾病的诊断和治疗的影响。
Ital J Pediatr. 2021 Mar 24;47(1):71. doi: 10.1186/s13052-021-01020-9.
3
COVID-19 pandemic: Pathophysiology and manifestations from the gastrointestinal tract.COVID-19 大流行：胃肠道的病理生理学和表现。
World J Gastroenterol. 2020 Aug 21;26(31):4579-4588. doi: 10.3748/wjg.v26.i31.4579.
4
Host Response to SARS-CoV2 and Emerging Variants in Pre-Existing Liver and Gastrointestinal Diseases.宿主对 SARS-CoV2 及现有肝脏和胃肠道疾病中新兴变异株的反应。
Front Cell Infect Microbiol. 2021 Oct 25;11:753249. doi: 10.3389/fcimb.2021.753249. eCollection 2021.
5
Pathologic Characteristics of Digestive Tract and Liver in Patients with Coronavirus Disease 2019.2019冠状病毒病患者消化道和肝脏的病理特征
Gastroenterol Clin North Am. 2023 Mar;52(1):201-214. doi: 10.1016/j.gtc.2022.09.003. Epub 2022 Oct 4.
6
Digestive manifestations in COVID-19: Prevalence and prognostic impact.COVID-19 的消化系统表现：患病率和预后影响。
Tunis Med. 2020 Aug-Sep;98(8-9):643-650.
7
COVID-19 extrapulmonary illness - special gastrointestinal and hepatic considerations.COVID-19 肺外疾病——特殊的胃肠道和肝脏注意事项。
Dis Mon. 2020 Sep;66(9):101064. doi: 10.1016/j.disamonth.2020.101064. Epub 2020 Jul 28.
8
COVID-19 induces gastrointestinal symptoms and affects patients' prognosis.新冠病毒可引起胃肠道症状，并影响患者的预后。
J Int Med Res. 2022 Oct;50(10):3000605221129543. doi: 10.1177/03000605221129543.
9
COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist.新型冠状病毒肺炎与胃肠道疾病：对胃肠病学家的启示。
Dig Dis. 2021;39(2):119-139. doi: 10.1159/000512152. Epub 2020 Oct 9.
10
COVID-19: gastrointestinal and hepatobiliary manifestations.新型冠状病毒肺炎：胃肠道和肝胆系统表现。
Hum Pathol. 2023 Feb;132:39-55. doi: 10.1016/j.humpath.2022.07.006. Epub 2022 Jul 16.
引用本文的文献
1
Global, regional, and national burden of gastritis and duodenitis from 1990 to 2021 with projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021.1990年至2021年胃炎和十二指肠炎的全球、区域和国家负担及到2050年的预测：全球疾病负担研究2021的系统分析
Int J Med Sci. 2025 May 10;22(11):2570-2582. doi: 10.7150/ijms.109762. eCollection 2025.
2
Temporal, spatial and demographic distributions characteristics of COVID-19 symptom clusters from chinese medicine perspective: a systematic cross-sectional study in China from 2019 to 2023.从中医角度看新型冠状病毒肺炎症状群的时间、空间和人口统计学分布特征：一项2019年至2023年在中国开展的系统性横断面研究
Chin Med. 2024 Dec 18;19(1):171. doi: 10.1186/s13020-024-01043-4.
3
Navigating new horizons in inflammatory bowel disease: Integrative approaches and innovations.在炎症性肠病领域的新探索：综合方法与创新。
World J Gastroenterol. 2024 Nov 7;30(41):4411-4416. doi: 10.3748/wjg.v30.i41.4411.
4
Semi-quantitative CT score reflecting the degree of pulmonary infection as a risk factor of hypokalemia in COVID-19 patients: a cross-sectional study.半定量CT评分反映肺部感染程度作为COVID-19患者低钾血症的危险因素：一项横断面研究。
Front Med (Lausanne). 2024 Oct 21;11:1366545. doi: 10.3389/fmed.2024.1366545. eCollection 2024.
5
Recent advances in COVID-19-induced liver injury: causes, diagnosis, and management.新型冠状病毒肺炎相关肝损伤的研究进展：病因、诊断与治疗。
Inflammopharmacology. 2024 Oct;32(5):2649-2680. doi: 10.1007/s10787-024-01535-7. Epub 2024 Aug 10.
6
COVID-19, Possible Hepatic Pathways and Alcohol Abuse-What Do We Know up to 2023?2023 年关于 COVID-19、可能的肝脏途径和酒精滥用，我们了解多少？
Int J Mol Sci. 2024 Feb 12;25(4):2212. doi: 10.3390/ijms25042212.
7
Drug-Induced Acute Pancreatitis in Adults: Focus on Antimicrobial and Antiviral Drugs, a Narrative Review.成人药物性急性胰腺炎：聚焦于抗菌药物和抗病毒药物，一篇叙述性综述
Antibiotics (Basel). 2023 Sep 29;12(10):1495. doi: 10.3390/antibiotics12101495.
本文引用的文献
1
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case-Control Study (COVID-19-EII).炎症性肠病中新冠病毒病的危险因素：一项基于西班牙炎症性肠病注册数据库（ENEIDA）的全国性病例对照研究（COVID-19-EII）
J Clin Med. 2022 Dec 19;11(24):7540. doi: 10.3390/jcm11247540.
2
COVID-19 susceptibility and clinical outcomes in inflammatory bowel disease: An updated systematic review and meta-analysis.COVID-19 易感性和炎症性肠病的临床结局：更新的系统评价和荟萃分析。
Rev Med Virol. 2023 Mar;33(2):e2414. doi: 10.1002/rmv.2414. Epub 2022 Dec 11.
3
Acute pancreatitis as an adverse effect of COVID-19 vaccination.急性胰腺炎作为新冠病毒疫苗接种的一种不良反应。
SAGE Open Med Case Rep. 2022 Oct 24;10:2050313X221131169. doi: 10.1177/2050313X221131169. eCollection 2022.
4
Risk of adverse outcomes in inflammatory bowel disease patients infected with SARS-CoV-2: a systematic review and meta-analysis.SARS-CoV-2 感染对炎症性肠病患者不良结局风险的系统评价和荟萃分析。
Int J Colorectal Dis. 2022 Nov;37(11):2277-2289. doi: 10.1007/s00384-022-04265-w. Epub 2022 Oct 22.
5
Acute Pancreatitis in a Patient With Recent History of SARS-CoV-2 Infection.一名近期有SARS-CoV-2感染史患者的急性胰腺炎
Cureus. 2022 Sep 11;14(9):e29032. doi: 10.7759/cureus.29032. eCollection 2022 Sep.
6
Acute liver injury and IgG4-related autoimmune pancreatitis following mRNA-based COVID-19 vaccination.基于mRNA的COVID-19疫苗接种后出现急性肝损伤和IgG4相关性自身免疫性胰腺炎。
Hepatol Forum. 2022 Sep 23;3(3):97-99. doi: 10.14744/hf.2022.2022.0019. eCollection 2022 Sep.
7
Acute pancreatitis in pregnancy following COVID-19 vaccine: a case report.妊娠期接种 COVID-19 疫苗后发生急性胰腺炎：病例报告。
J Med Case Rep. 2022 Sep 29;16(1):354. doi: 10.1186/s13256-022-03607-0.
8
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study.COVID-19 疫苗接种后第三剂后炎症性肠病免疫抑制患者的抗体和 T 细胞反应（VIP）：一项多中心、前瞻性、病例对照研究。
Lancet Gastroenterol Hepatol. 2022 Nov;7(11):1005-1015. doi: 10.1016/S2468-1253(22)00274-6. Epub 2022 Sep 9.
9
Comparison the effects and side effects of Covid-19 vaccination in patients with inflammatory bowel disease (IBD): a systematic scoping review.比较 COVID-19 疫苗接种在炎症性肠病（IBD）患者中的效果和副作用：系统范围综述。
BMC Gastroenterol. 2022 Aug 20;22(1):393. doi: 10.1186/s12876-022-02460-1.
10
IBD Flare in the COVID-19 Pandemic: Therapy Discontinuation Is to Blame.新冠疫情期间的炎症性肠病发作：治疗中断难辞其咎。
Inflamm Bowel Dis. 2023 May 2;29(5):834-836. doi: 10.1093/ibd/izac173.
Zotero 插件